Futura Medical (AIM: FUM), a leader in innovative sexual health products, reported a strong 2024 performance, delivering its maiden profit alongside revenue growth to nearly £14 million. Its flagship erectile dysfunction (ED) treatment, Eroxon®, has launched across 15 countries, including the USA, with expansion into over 20 markets anticipated by the end of 2025. Eroxon, the first FDA-cleared over-the-counter topical ED treatment, offers a unique 10-minute onset, differentiating it from traditional oral therapies. Futura’s focused growth strategy, robust commercial partnerships, and disciplined financial management underpin its positive outlook, despite early-stage market variances and evolving consumer behaviors. The company continues to build its product pipeline with Eroxon® Intense targeting enhanced efficacy, and WSD4000 addressing the significant unmet need in female sexual health. With a gross margin of 70%, £6.6 million in cash, and strong IP protection through 2040, Futura remains well-capitalized to fund ongoing R&D and global commercialization initiatives. Management emphasizes confidence in long-term revenue growth, profitability, and expanding its footprint in the $3.5 billion global ED market and beyond.